In addition, clinical studies have found that among patients receiving gastric cancer immunotherapy (nivolumab ± ipilimumab [85], nivolumab [86]), patients with high expression of LAG3 in the gastric mucosal immune microenvironment have a better prognosis. This evidence concerns the gene LAG3 and gastric cancer.